Concepts (209)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Drug Interactions | 3 | 2021 | 18 | 1.700 |
Why?
|
| Anesthetics | 2 | 2021 | 2 | 1.680 |
Why?
|
| Perioperative Period | 2 | 2021 | 2 | 1.680 |
Why?
|
| Pharmaceutical Preparations | 2 | 2021 | 3 | 1.680 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 2 | 2021 | 12 | 1.670 |
Why?
|
| Chronic Disease | 2 | 2021 | 70 | 1.610 |
Why?
|
| Laryngoscopes | 2 | 2016 | 2 | 1.150 |
Why?
|
| Humans | 29 | 2022 | 2493 | 1.100 |
Why?
|
| HIV Infections | 4 | 2016 | 91 | 0.790 |
Why?
|
| Pain, Postoperative | 8 | 2017 | 11 | 0.770 |
Why?
|
| Laryngoscopy | 2 | 2016 | 2 | 0.720 |
Why?
|
| Intubation, Intratracheal | 2 | 2016 | 7 | 0.720 |
Why?
|
| Pain Measurement | 5 | 2017 | 39 | 0.670 |
Why?
|
| Middle Aged | 14 | 2017 | 799 | 0.640 |
Why?
|
| Postoperative Complications | 3 | 2016 | 42 | 0.600 |
Why?
|
| Video-Assisted Surgery | 1 | 2016 | 1 | 0.580 |
Why?
|
| Fiber Optic Technology | 1 | 2016 | 1 | 0.580 |
Why?
|
| Cervical Vertebrae | 1 | 2016 | 3 | 0.580 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2017 | 11 | 0.570 |
Why?
|
| Betamethasone | 1 | 2015 | 3 | 0.540 |
Why?
|
| Low Back Pain | 1 | 2015 | 5 | 0.540 |
Why?
|
| Steroids | 1 | 2015 | 7 | 0.540 |
Why?
|
| Male | 16 | 2020 | 1649 | 0.540 |
Why?
|
| Adult | 10 | 2016 | 807 | 0.530 |
Why?
|
| Obesity | 1 | 2016 | 102 | 0.510 |
Why?
|
| Aged | 8 | 2017 | 607 | 0.510 |
Why?
|
| Female | 15 | 2020 | 1733 | 0.500 |
Why?
|
| Ambulatory Surgical Procedures | 4 | 2016 | 5 | 0.470 |
Why?
|
| Analgesics, Opioid | 6 | 2016 | 35 | 0.470 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2017 | 23 | 0.450 |
Why?
|
| Cardiovascular Surgical Procedures | 1 | 2012 | 1 | 0.450 |
Why?
|
| HIV-1 | 1 | 2012 | 10 | 0.450 |
Why?
|
| Antiretroviral Therapy, Highly Active | 4 | 2016 | 8 | 0.420 |
Why?
|
| Prospective Studies | 6 | 2017 | 121 | 0.390 |
Why?
|
| United States | 2 | 2021 | 324 | 0.380 |
Why?
|
| Postoperative Nausea and Vomiting | 3 | 2020 | 3 | 0.330 |
Why?
|
| Pain Management | 3 | 2016 | 11 | 0.330 |
Why?
|
| Time Factors | 4 | 2016 | 120 | 0.320 |
Why?
|
| Equipment Design | 3 | 2016 | 9 | 0.320 |
Why?
|
| Anesthetics, Local | 2 | 2017 | 3 | 0.310 |
Why?
|
| Anxiety | 2 | 2017 | 20 | 0.300 |
Why?
|
| Patient Satisfaction | 4 | 2016 | 16 | 0.290 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 3 | 2016 | 16 | 0.280 |
Why?
|
| Anesthesia, Conduction | 2 | 2016 | 2 | 0.280 |
Why?
|
| Perioperative Care | 2 | 2016 | 2 | 0.280 |
Why?
|
| Young Adult | 2 | 2016 | 175 | 0.270 |
Why?
|
| Aged, 80 and over | 2 | 2016 | 246 | 0.270 |
Why?
|
| Electrocardiography | 2 | 2022 | 18 | 0.260 |
Why?
|
| Retrospective Studies | 5 | 2016 | 210 | 0.260 |
Why?
|
| Pneumothorax | 1 | 2022 | 1 | 0.230 |
Why?
|
| Treatment Outcome | 4 | 2015 | 119 | 0.210 |
Why?
|
| Anesthesiology | 1 | 2020 | 1 | 0.200 |
Why?
|
| Educational Measurement | 1 | 2020 | 6 | 0.190 |
Why?
|
| Internship and Residency | 1 | 2020 | 10 | 0.190 |
Why?
|
| Clinical Competence | 1 | 2020 | 13 | 0.190 |
Why?
|
| Adenosine | 2 | 2017 | 2 | 0.190 |
Why?
|
| Midazolam | 2 | 2016 | 2 | 0.190 |
Why?
|
| Anesthetics, Intravenous | 2 | 2016 | 2 | 0.190 |
Why?
|
| Double-Blind Method | 6 | 2017 | 48 | 0.180 |
Why?
|
| Dexamethasone | 2 | 2017 | 27 | 0.180 |
Why?
|
| Anesthesia | 2 | 2016 | 3 | 0.170 |
Why?
|
| Intercostal Nerves | 1 | 2017 | 1 | 0.160 |
Why?
|
| Autonomic Nerve Block | 1 | 2017 | 2 | 0.160 |
Why?
|
| Analgesia, Epidural | 1 | 2017 | 4 | 0.160 |
Why?
|
| Interleukin-4 | 1 | 2017 | 7 | 0.160 |
Why?
|
| Hippocampus | 1 | 2017 | 13 | 0.150 |
Why?
|
| Cognitive Dysfunction | 1 | 2017 | 5 | 0.150 |
Why?
|
| Coronary Stenosis | 1 | 2017 | 2 | 0.150 |
Why?
|
| Carbon Dioxide | 1 | 2017 | 12 | 0.150 |
Why?
|
| Positron-Emission Tomography | 1 | 2017 | 3 | 0.150 |
Why?
|
| Facial Expression | 1 | 2017 | 1 | 0.150 |
Why?
|
| Manifest Anxiety Scale | 1 | 2017 | 1 | 0.150 |
Why?
|
| Preoperative Period | 1 | 2017 | 1 | 0.150 |
Why?
|
| Analgesia | 1 | 2016 | 12 | 0.150 |
Why?
|
| Preanesthetic Medication | 1 | 2016 | 1 | 0.150 |
Why?
|
| Mental Recall | 1 | 2016 | 1 | 0.150 |
Why?
|
| Propofol | 1 | 2016 | 1 | 0.150 |
Why?
|
| Inflammation | 1 | 2017 | 44 | 0.150 |
Why?
|
| Hypnotics and Sedatives | 1 | 2016 | 3 | 0.150 |
Why?
|
| Arthroplasty, Replacement, Knee | 1 | 2016 | 1 | 0.150 |
Why?
|
| Arthroplasty, Replacement, Hip | 1 | 2016 | 4 | 0.150 |
Why?
|
| Bariatric Surgery | 1 | 2016 | 1 | 0.140 |
Why?
|
| Immobilization | 1 | 2016 | 2 | 0.140 |
Why?
|
| Single-Blind Method | 1 | 2016 | 5 | 0.140 |
Why?
|
| Quality Assurance, Health Care | 1 | 2016 | 13 | 0.140 |
Why?
|
| Hemodynamics | 1 | 2016 | 9 | 0.140 |
Why?
|
| Ritonavir | 1 | 2016 | 1 | 0.140 |
Why?
|
| HIV Protease Inhibitors | 1 | 2016 | 2 | 0.140 |
Why?
|
| Anti-Retroviral Agents | 1 | 2015 | 3 | 0.140 |
Why?
|
| Carotid Arteries | 1 | 2015 | 4 | 0.140 |
Why?
|
| Anesthetics, Dissociative | 1 | 2015 | 1 | 0.140 |
Why?
|
| Heart, Artificial | 1 | 2015 | 1 | 0.140 |
Why?
|
| Injections, Epidural | 1 | 2015 | 1 | 0.140 |
Why?
|
| Ketamine | 1 | 2015 | 1 | 0.140 |
Why?
|
| Sternotomy | 1 | 2015 | 1 | 0.140 |
Why?
|
| Adolescent | 1 | 2016 | 305 | 0.130 |
Why?
|
| Cardiomyopathies | 1 | 2014 | 1 | 0.130 |
Why?
|
| HIV-Associated Lipodystrophy Syndrome | 1 | 2014 | 1 | 0.130 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2015 | 118 | 0.130 |
Why?
|
| Arthroplasty | 1 | 2014 | 1 | 0.130 |
Why?
|
| Emergency Nursing | 1 | 2014 | 1 | 0.130 |
Why?
|
| Prescription Drug Misuse | 1 | 2014 | 1 | 0.130 |
Why?
|
| Prescription Drug Diversion | 1 | 2014 | 1 | 0.130 |
Why?
|
| Nursing Staff, Hospital | 1 | 2014 | 2 | 0.130 |
Why?
|
| Osteoarthritis, Hip | 1 | 2014 | 3 | 0.130 |
Why?
|
| Fentanyl | 1 | 2014 | 1 | 0.130 |
Why?
|
| Opioid-Related Disorders | 1 | 2014 | 7 | 0.130 |
Why?
|
| Myelography | 1 | 2014 | 1 | 0.130 |
Why?
|
| Spinal Cord Neoplasms | 1 | 2014 | 1 | 0.130 |
Why?
|
| Spinal Diseases | 1 | 2014 | 1 | 0.130 |
Why?
|
| Spinal Puncture | 1 | 2014 | 1 | 0.130 |
Why?
|
| Ventricular Function, Left | 1 | 2014 | 7 | 0.130 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2014 | 12 | 0.130 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2014 | 13 | 0.130 |
Why?
|
| Coronary Circulation | 1 | 2014 | 1 | 0.130 |
Why?
|
| Hypercapnia | 1 | 2014 | 1 | 0.130 |
Why?
|
| Lung Neoplasms | 1 | 2014 | 25 | 0.120 |
Why?
|
| Cough | 2 | 2014 | 2 | 0.120 |
Why?
|
| Viral Load | 1 | 2012 | 6 | 0.110 |
Why?
|
| Disposable Equipment | 1 | 2012 | 1 | 0.110 |
Why?
|
| Laparoscopy | 1 | 2012 | 1 | 0.110 |
Why?
|
| Acupressure | 1 | 2012 | 1 | 0.110 |
Why?
|
| Animals | 4 | 2017 | 1238 | 0.100 |
Why?
|
| Lymphocyte Depletion | 1 | 2011 | 1 | 0.100 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2011 | 5 | 0.100 |
Why?
|
| Adenoviridae | 1 | 2011 | 9 | 0.100 |
Why?
|
| Neoplasms, Experimental | 1 | 2011 | 7 | 0.100 |
Why?
|
| Ibuprofen | 1 | 2010 | 1 | 0.100 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2010 | 1 | 0.100 |
Why?
|
| Pyrazoles | 1 | 2010 | 9 | 0.100 |
Why?
|
| Sulfonamides | 1 | 2010 | 10 | 0.100 |
Why?
|
| Activities of Daily Living | 3 | 2020 | 10 | 0.100 |
Why?
|
| Health Personnel | 2 | 2022 | 13 | 0.090 |
Why?
|
| Anesthesia Recovery Period | 1 | 2009 | 1 | 0.090 |
Why?
|
| Isoflurane | 1 | 2009 | 1 | 0.090 |
Why?
|
| Methyl Ethers | 1 | 2009 | 1 | 0.090 |
Why?
|
| Anesthetics, Inhalation | 1 | 2009 | 1 | 0.090 |
Why?
|
| Anesthesia, Inhalation | 1 | 2009 | 2 | 0.090 |
Why?
|
| Surveys and Questionnaires | 3 | 2016 | 97 | 0.090 |
Why?
|
| Antiemetics | 2 | 2020 | 2 | 0.080 |
Why?
|
| Age Factors | 2 | 2016 | 90 | 0.070 |
Why?
|
| Dogs | 2 | 2017 | 5 | 0.070 |
Why?
|
| Vasodilator Agents | 2 | 2017 | 4 | 0.070 |
Why?
|
| Reproducibility of Results | 2 | 2017 | 52 | 0.070 |
Why?
|
| Disease Models, Animal | 2 | 2017 | 143 | 0.060 |
Why?
|
| Qualitative Research | 1 | 2022 | 21 | 0.060 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2022 | 7 | 0.060 |
Why?
|
| Pandemics | 1 | 2022 | 22 | 0.060 |
Why?
|
| Chi-Square Distribution | 2 | 2012 | 21 | 0.050 |
Why?
|
| Los Angeles | 2 | 2012 | 210 | 0.050 |
Why?
|
| Aftercare | 1 | 2020 | 1 | 0.050 |
Why?
|
| Checklist | 1 | 2020 | 1 | 0.050 |
Why?
|
| Patient Discharge | 1 | 2020 | 8 | 0.050 |
Why?
|
| Goals | 1 | 2020 | 2 | 0.050 |
Why?
|
| Administration, Intravenous | 1 | 2017 | 1 | 0.040 |
Why?
|
| Microglia | 1 | 2017 | 2 | 0.040 |
Why?
|
| Drug Therapy, Combination | 1 | 2017 | 30 | 0.040 |
Why?
|
| Multimodal Imaging | 1 | 2017 | 1 | 0.040 |
Why?
|
| Exercise Test | 1 | 2017 | 3 | 0.040 |
Why?
|
| Sensitivity and Specificity | 1 | 2017 | 45 | 0.040 |
Why?
|
| Pain, Procedural | 1 | 2016 | 1 | 0.040 |
Why?
|
| Orthopedic Procedures | 1 | 2016 | 1 | 0.040 |
Why?
|
| Conscious Sedation | 1 | 2016 | 2 | 0.040 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2017 | 179 | 0.040 |
Why?
|
| Hospitals | 1 | 2016 | 3 | 0.040 |
Why?
|
| Aging | 1 | 2017 | 101 | 0.040 |
Why?
|
| Anesthesia, General | 1 | 2016 | 3 | 0.040 |
Why?
|
| Cohort Studies | 1 | 2016 | 56 | 0.040 |
Why?
|
| Infusions, Intravenous | 1 | 2015 | 11 | 0.030 |
Why?
|
| Prosthesis Implantation | 1 | 2015 | 11 | 0.030 |
Why?
|
| Blood Pressure | 1 | 2015 | 45 | 0.030 |
Why?
|
| Health Care Surveys | 1 | 2014 | 10 | 0.030 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2014 | 1 | 0.030 |
Why?
|
| Myocardial Contraction | 1 | 2014 | 2 | 0.030 |
Why?
|
| Substance Abuse Detection | 1 | 2014 | 1 | 0.030 |
Why?
|
| Professional Misconduct | 1 | 2014 | 2 | 0.030 |
Why?
|
| Movement | 1 | 2014 | 1 | 0.030 |
Why?
|
| Spinal Cord Compression | 1 | 2014 | 1 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2014 | 32 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2014 | 40 | 0.030 |
Why?
|
| Triglycerides | 1 | 2014 | 36 | 0.030 |
Why?
|
| Myocardium | 1 | 2014 | 15 | 0.030 |
Why?
|
| Pneumonectomy | 1 | 2014 | 1 | 0.030 |
Why?
|
| Thoracic Surgery, Video-Assisted | 1 | 2014 | 1 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2015 | 267 | 0.030 |
Why?
|
| Postoperative Care | 1 | 2014 | 2 | 0.030 |
Why?
|
| Recurrence | 1 | 2014 | 9 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2014 | 12 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2014 | 22 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2014 | 24 | 0.030 |
Why?
|
| Image Enhancement | 1 | 2014 | 1 | 0.030 |
Why?
|
| Oximetry | 1 | 2014 | 1 | 0.030 |
Why?
|
| Risk Factors | 1 | 2014 | 240 | 0.030 |
Why?
|
| Ondansetron | 1 | 2012 | 1 | 0.030 |
Why?
|
| Serotonin Antagonists | 1 | 2012 | 2 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2012 | 17 | 0.030 |
Why?
|
| CTLA-4 Antigen | 1 | 2011 | 2 | 0.030 |
Why?
|
| Cancer Vaccines | 1 | 2011 | 3 | 0.030 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2011 | 14 | 0.030 |
Why?
|
| Adjuvants, Immunologic | 1 | 2011 | 6 | 0.030 |
Why?
|
| Immunotherapy | 1 | 2011 | 9 | 0.030 |
Why?
|
| Antigens, CD | 1 | 2011 | 18 | 0.030 |
Why?
|
| Celecoxib | 1 | 2010 | 1 | 0.030 |
Why?
|
| Italy | 1 | 2010 | 1 | 0.030 |
Why?
|
| Placebo Effect | 1 | 2010 | 4 | 0.030 |
Why?
|
| Recovery of Function | 1 | 2010 | 2 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2010 | 19 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2011 | 185 | 0.020 |
Why?
|
| Mice | 1 | 2011 | 508 | 0.020 |
Why?
|